China

Medical content can be viewed in the form of articles, animation, and videos.

The Wuxi Xinwu District Court held that a 2015 land transfer between Wuxi Yilin and Wuxi New District Phoenix Hospital was legal.

It will also boost the headcount in its Shanghai R&D centre to 1,000.

Blame the two-invoice system.

The entrance of Indian players may cut prices further by 30%.

The effects of regulatory change on the sales of patented medicine are expected to be mild.

China-based Weimai’s $155m funding round was one of the quarter’s notable deals.

The number of deals fell to 62 transactions in the same period.

Over the next decade, an estimated $2t investment into Universal Health Coverage (UHC) schemes is expected to land in Asia. The developing markets in the region have traditionally under-funded healthcare at a rate of about 5% of GDP (compared to the average of 12% in OECD countries like Australia and Japan). Whilst some emerging markets in Asia continue to grapple with lingering infection control, all are shifting focus to the more advanced lifestyle diseases.

The plan by the State Council to cut high-value medical consumables prices deals a heavy blow.

UFH is expected to be given the exclusive right to manage New Frontier Group’s 64,000 sqm flagship Shenzhen city center hospital.

Tech giants such as Ping An and Tencent are tapping into blockchain and AI to address the sector’s talent shortage.

This follows the accounting scandal of a pharmaceutical firm accused of fabricating revenue and costs.

The 25% hike imposed in 2018 have resulted in a sharp fall in imports of MRI systems, X-ray apparatus, patient monitors and ophthalmic instruments from the US.

Medical device approvals in China plunged 38% in 2018 to 5,528 successful registrations.

The State Medical Insurance Administration is set to roll out its new NRDL and price negotiation list in June.